GlassScriptPhysician profile
Nancy Bouloute
NPI 1265984991
$7,663.36
in general payments reported to CMS, 2019-2025
28 companies · $901 in 2025
The $901 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,059 · 2022: $1,735 · 2023: $2,542 · 2024: $1,427 · 2025: $901.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,775 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,775.45 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,877.05 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,103.86 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $896.89 | 2022-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $793.98 | 2021-2025 | Jardiance, Synjardy, Trijardy Xr |
| Glaxosmithkline, LLC. | $655.75 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $434.03 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Exact Sciences Corporation | $360.20 | 2023-2024 | Cologuard Collection Kit |
| Pfizer INC. | $198.02 | 2022-2025 | |
| Novo Nordisk INC | $162.12 | 2021-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $139.07 | 2022-2024 | |
| Amgen INC. | $131.86 | 2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $130.00 | 2025 | Caplyta |
| Abbott Laboratories | $124.99 | 2023 | Freestyle Libre 3 |
| Astellas Pharma US INC | $108.48 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $101.54 | 2022-2023 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $84.33 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $79.44 | 2022 | |
| Gilead Sciences, INC. | $50.37 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $36.76 | 2022-2023 | |
| Phadia US INC. | $34.33 | 2022-2023 | Immunocap |
| Almatica Pharma LLC | $27.35 | 2021-2022 | |
| Angiodynamics, INC. | $27.27 | 2023 | Auryon Laser System 100-120 Vac |
| Tactile Systems Technology INC | $24.37 | 2025 | Flexitouch Plus, Nimbl |
| Actelion Pharmaceuticals US, INC. | $19.09 | 2023 | Uptravi, Opsumit |
| Insightec,INC | $16.91 | 2025 | Exablate |
| Seqirus USA INC | $15.43 | 2025 | Fluad, Flucelvax |
| Alvogen INC | $15.41 | 2022 | |
| Amarin Pharma, INC. | $14.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Bouloute listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.